Montelukast Puren

Montelukast, the active ingredient in Montelukast Puren, is a leukotriene receptor antagonist presented as an oral tablet for oral use. It is used to manage asthma, exercise‑induced bronchoconstriction, and allergic rhinitis in adults and children by blocking cysteinyl leukotriene receptors, thereby reducing airway inflammation and bronchoconstriction.

GNH USA supplies Montelukast Puren as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelukast is a leukotriene receptor antagonist used to treat conditions involving airway inflammation and allergic responses. - Asthma: Improves control of chronic asthma symptoms and reduces frequency of exacerbations. - Exercise‑induced bronchoconstriction: Prevents narrowing of the airways triggered by physical activity. - Allergic rhinitis: Relieves nasal congestion, sneezing and itching associated with seasonal allergies.

Montelukast may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Headache: mild to moderate head pain. - Upper respiratory infection: sore throat, nasal congestion, or mild cough. - Cough: occasional dry or productive cough. - Abdominal pain: mild stomach discomfort.

Serious or Rare Side Effects: - Mood changes: depression, anxiety, or suicidal thoughts. - Allergic reactions: rash, hives, or swelling of the face. - Liver enzyme elevation: signs of hepatic dysfunction.

Montelukast should be used with caution in specific clinical situations. - Pregnancy: safety not established; use only if benefit outweighs risk. - Breastfeeding: unknown; consider potential effects on the infant. - Hepatic impairment: monitor liver function and adjust therapy if needed. - Concomitant enzyme inducers (e.g., phenobarbital, rifampin): may reduce effectiveness. - Age restrictions: not recommended for children under 12 months for asthma treatment. - Store at ambient temperature: keep below 25°C, retain in the original pack, and protect from moisture.

Montelukast can interact with other medicines, requiring attention to potential changes in efficacy or safety.

Major Interactions (Avoid): - Phenobarbital: induces metabolism, decreasing montelukast levels. - Rifampin: strong enzyme inducer that reduces drug exposure. - Strong CYP3A4 inhibitors: may increase plasma concentrations.

Moderate Interactions (Monitor Closely): - Antidepressants (e.g., SSRIs): possible additive mood‑related effects. - Antihistamines: may cause additive sedation in sensitive individuals. - Warfarin: potential alteration of INR; monitor coagulation parameters.